Royalty Pharma Plc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Royalty Pharma Plc (RPRX) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Royalty Pharma Plc vs Its Competitors
- TTM: Trailing 12-month revenue of 2,536M vs 646,146M combined for its competitors (0.4% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+6.3% annualized vs trailing 12 months), vs accelerating (+2.6%) for its tracked peer group.
- Growth: Royalty Pharma Plc generated 16.5% revenue growth year over year in Q2 2026, vs 11.6% for its competitors combined.
- Profitability: Its 12.1% net margin compares with 7.2% for the peer group.
- Scale: Royalty Pharma Plc ranks #17 of 548 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 0.6% of industry market cap.
- Peer revenue share: Royalty Pharma Plc accounted for 0.4% of combined revenue among its tracked peer group, up from 0.4% a year earlier.
- Peer differentiation: Revenue per employee of $25.36M compares with $0.92M for the peer group (27.5x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
RPRX Sales vs. its Competitors, Q2 2026
Royalty Pharma Plc reported revenue growth of 16.50 % year on year in Q2 2026, above its competitors' combined revenue growth of 11.59 %.
With a net margin of 12.09 %, Royalty Pharma Plc achieved higher profitability than its competitors (7.16 %).
Royalty Pharma Plc generated 0.40 % of the combined sales of its peer group, up from 0.39 % a year earlier.
Royalty Pharma Plc vs. its Competitors, Q2 2026
Revenue growth, year on year
Net income growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Royalty Pharma Plc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Royalty Pharma Plc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Royalty Pharma Plc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (8) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (4) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Royalty Pharma Plc's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 8.9% year over year, combined, vs 16.5% for Royalty Pharma Plc. Royalty Pharma Plc's share of combined industry revenue moved from 0.12% to 0.13%, a gain of 0.01 percentage points.
Royalty Pharma Plc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Royalty Pharma Plc | Yes | Yes | Yes | No |
| Competitors combined (89) | ||||
| Similar-Size Competitors (10) | ||||
| Similar Growth & Profitability (8) | 100.00 % (7 of 7) | 100.00 % (8 of 8) | 75.00 % (6 of 8) | 0.00 % (0 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
RPRX Stock Performance relative to its Competitors
RPRX Stock Performance relative to Similar-Size Competitors
RPRX Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Ventyx Biosciences Inc | 282.9% | Outperformed |
| 2 | Damora Therapeutics Inc | 282.9% | Outperformed |
| 3 | 180 Life Sciences Corp | 282.9% | Outperformed |
| 4 | Dianthus Therapeutics Inc | 282.9% | Outperformed |
| 5 | Kiniksa Pharmaceuticals International Plc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Royalty Pharma Plc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Royalty Pharma Plc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Royalty Pharma Plc |
37,623.89 | 2,536.00 |
 Eli Lilly And Company |
1,266,591.05 | 86,462.00 |
 Johnson and Johnson |
676,597.15 | 99,335.00 |
 Abbvie Inc |
522,438.76 | 66,014.00 |
 Merck and Co Inc |
371,339.80 | 66,569.00 |
 Novartis Ag |
322,535.90 | 56,674.00 |
| SUBTOTAL | 5,021,538.24 | 845,107.07 |
Sign in to see all competitors of Royalty Pharma Plc.
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Royalty Pharma Plc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Royalty Pharma Plc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Eli Lilly And Company | Reportable 100.00 % |
| Johnson and Johnson | Oncology 29.93 % |
| Merck and Co Inc | Pharmaceutical segment 88.88 % |
| Amgen Inc | Reportable 100.00 % |
| Abbott Laboratories | Diabetes Care 17.78 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Royalty Pharma Plc.
Royalty Pharma Plc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Royalty Pharma Plc | 37,624 | 25,359,980 | 12,081,580 |
| Eli Lilly And Company | 1,266,591 | 1,729,240 | 551,594 |
| Johnson and Johnson | 676,597 | 705,504 | 114,311 |
| Abbvie Inc | 522,439 | 1,158,140 | 181,509 |
| Merck and Co Inc | 371,340 | 887,587 | 42,267 |
| Novartis Ag | 322,536 | 752,973 | 185,566 |
| PEERS TOTAL | 4,983,914 | 921,773 | 129,023 |
Sign in to see all peers for Royalty Pharma Plc.
Royalty Pharma Plc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Eli Lilly And Company | United States 62.04 % |
| Johnson and Johnson | United States 58.90 % |
| Merck and Co Inc | EMEA 23.60 % |
| Gilead Sciences Inc | United States 76.66 % |
| Abbott Laboratories | Non-US 61.62 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Royalty Pharma Plc.
Royalty Pharma Plc's Position in Industry Market Structure
Market-capitalization share and concentration across all 497 companies in Royalty Pharma Plc's industry classification, broader than the peer set above. Market cap in millions of $.Royalty Pharma Plc ranks #17 of 497 companies by market capitalization in its industry, holding 0.63 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 885, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,267,016 | 21.36 % |
| 2 | Johnson and Johnson | 674,248 | 11.37 % |
| 3 | Beone Medicines Ltd | 568,696 | 9.59 % |
| 4 | Abbvie Inc | 522,144 | 8.80 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Astrazeneca Plc | 1,234 | 5.2% |
| 17 | Royalty Pharma Plc | 37,624 | 0.63 % |
Market cap and industry share for the rest of Royalty Pharma Plc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-04.
Royalty Pharma Plc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 12 | Bristol myers Squibb Company | 131,461 | 37.55 % |
| 13 | Sanofi | 116,358 | -6.54 % |
| 14 | Gsk Plc | 104,451 | 8.85 % |
| 15 | Regeneron Pharmaceuticals Inc | 98,651 | 52.02 % |
| 16 | Teva Pharmaceutical Industries Limited | 1,234 | 12.3% |
| 17 | Royalty Pharma Plc | 37,624 | 78.54 % |
| 18 | Zoetis Inc | 1,234 | 12.3% |
| 19 | Spyre Therapeutics Inc | 1,234 | 12.3% |
| 20 | Takeda Pharmaceutical Company Limited | 1,234 | 12.3% |
| 21 | United Therapeutics Corporation | 1,234 | 12.3% |
| 22 | Roivant Sciences Ltd | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Royalty Pharma Plc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-04. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Royalty Pharma Plc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (404 companies). See the full Major Pharmaceutical Preparations industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 59.66 % | 32.73 % (avg) | +26.9 pp |
| Operating Margin | 38.90 % | industry median | +39.0 pp |
| EBITDA Margin | 50.42 % | -4.81 % (avg) | +55.2 pp |
| Capital Intensity (Capex / Revenue) | - | 7.48 % (avg) | - |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Royalty Pharma Plc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (404 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | 27.8x | 27.6x | +0.2x |
| EV / EBITDA | 29.2x | 15.9x | +13.3x |
| P/B | 3.0x | 4.2x | -1.2x |
| Return on Equity | 12.37 % | industry aggregate | -4.78 % |
| Return on Invested Capital | 3.09 % | -7.48 % (avg) | 10.57 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Royalty Pharma Plc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue Growth | 500.00 % | 7.87 % | -2.28 % | 5.24 % | -3.86 % | 5.06 % |
| Operating Margin | 75.17 % | 62.49 % | 13.73 % | 63.37 % | 57.10 % | 43.49 % |
| Return on Invested Capital | 6.98 % | 4.53 % | 0.99 % | 5.08 % | 4.28 % | 3.36 % |
| P/E | 38.7x | 26.3x | 105.2x | 10.9x | 13.9x | 21.4x |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Royalty Pharma Plc's Strategic Group Map
Royalty Pharma Plc is shown in red; its closest peers by combined growth, margin and ROIC are labeled. See Methodology: Strategic Group Map for how this chart is built.
Royalty Pharma Plc's trailing-12-month revenue growth of 10.0% and operating margin of 38.9% compares with an average of 8.9% growth and 36.6% margin across its 8 closest peers by combined growth, margin and ROIC -- Royalty Pharma Plc sits above that peer average on growth and above it on margin.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Royalty Pharma Plc's BCG Growth-Share Matrix
See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.
Royalty Pharma Plc falls in the Dog quadrant: relative market share of 0.03x vs its largest competitor, in an industry growing revenue 8.0% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Royalty Pharma Plc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 885 (see Industry Market Structure & Concentration above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Royalty Pharma Plc's dedicated Suppliers and Customers pages, not here.
Royalty Pharma Plc's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Royalty Pharma Plc falls in the Low attractiveness / Medium strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Royalty Pharma Plc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Operating margin 39.0 points above the industry median.
- Latest-quarter revenue run-rate is accelerating (+6.3% annualized vs trailing 12 months).
- Outperforming the U.S.A. 500 over the trailing 12 months.
Weaknesses
- Low relative market share vs the industry leader (0.03x).
Opportunities
- A meaningful share of competitors (33.70 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: see Methodology: SWOT Analysis.
Royalty Pharma Plc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Royalty Pharma Plc | 1.27 | 2.81 | 0.93 |
| Eli Lilly And Company | 0.16 | 1.44 | 1.44 |
| Johnson and Johnson | 0.36 | 1.04 | 0.60 |
| Abbvie Inc | 0.19 | 0.79 | - |
| Merck and Co Inc | 0.40 | 1.46 | 1.01 |
| Novartis Ag | 0.42 | 1.12 | 0.02 |
Sign in to see all peers for Royalty Pharma Plc.
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Royalty Pharma Plc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Royalty Pharma Plc | Q2 2026 | +16.5 % | +153.3 % |
| Eli Lilly And Company | Q3 2026 | +38.6 % | +15.6 % |
| Johnson and Johnson | Q3 2026 | +5.9 % | -95.9 % |
| Abbvie Inc | Q3 2026 | +10.3 % | +2,143.6 % |
| Merck and Co Inc | Q2 2026 | +5.1 % | - |
| Novartis Ag | Q4 2025 | +9.6 % | +17.0 % |
| PEERS TOTAL | +9.8 % | +0.3 % |
Sign in to see all peers for Royalty Pharma Plc.
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Royalty Pharma Plc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Royalty Pharma Plc | Q2 2026 | - | - |
| Eli Lilly And Company | Q3 2026 | +30.7 % | +52.2 % |
| Johnson and Johnson | Q3 2026 | +10.9 % | +17.7 % |
| Abbvie Inc | Q3 2026 | -19.2 % | -21.0 % |
| Merck and Co Inc | Q2 2026 | +23.6 % | +16.9 % |
| Novartis Ag | Q4 2025 | +18.3 % | +13.3 % |
Sign in to see all peers for Royalty Pharma Plc.
Royalty Pharma Plc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Royalty Pharma Plc | 6.15% | 5.45% | 12.37% |
| Eli Lilly And Company | 21.24% | 32.00% | 83.65% |
| Johnson and Johnson | 8.06% | 10.53% | 19.55% |
| Abbvie Inc | 7.48% | 12.87% | - |
| Merck and Co Inc | 2.42% | 3.24% | 6.59% |
| Novartis Ag | 12.59% | 12.62% | 30.00% |
Sign in to see all peers for Royalty Pharma Plc.
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Royalty Pharma Plc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Royalty Pharma Plc | 36.13 | 14.84 |
| Eli Lilly And Company | 46.03 | 14.65 |
| Johnson and Johnson | 41.80 | 6.81 |
| Abbvie Inc | 50.75 | 7.91 |
| Merck and Co Inc | 121.24 | 5.58 |
| Novartis Ag | 23.06 | 5.69 |
| PEERS AVERAGE | 42.15 | 5.94 |
Sign in to see all peers for Royalty Pharma Plc.
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.